Biogennix announced results of a detailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material. TrelCor is an dual-phase bone graft featuring a nanocrystalline hydroxycarbanoapatite (HCA) surface, specially engineered for bone formation.
The study was titled “Characterization of an Advanced Bone Graft Material with a Nanocrystalline Hydroxycarbanoapatite Surface and Dual Phase Composition.”
Using a variety of analytical techniques, the study confirmed TrelCor’s dual phase composition and a nanostructured HCA surface. Additional testing evaluated various advanced bone graft properties including bioactivity and in vivo stem cell stimulation. Results showed that TrelCor exhibited a robust bioactive response and was capable of stimulating bone forming cells.
The study’s findings underscore TrelCor’s efficacy in actively stimulating a bone formation response, which leads it to significantly outperforming traditional, first generation bone graft materials. TrelCor has undergone over 75,000 successful implantations.
Biogennix announced results of a detailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material. TrelCor is an dual-phase bone graft featuring a nanocrystalline hydroxycarbanoapatite (HCA) surface, specially engineered for bone formation.
The study was titled “Characterization of an Advanced Bone Graft...
Biogennix announced results of a detailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material. TrelCor is an dual-phase bone graft featuring a nanocrystalline hydroxycarbanoapatite (HCA) surface, specially engineered for bone formation.
The study was titled “Characterization of an Advanced Bone Graft Material with a Nanocrystalline Hydroxycarbanoapatite Surface and Dual Phase Composition.”
Using a variety of analytical techniques, the study confirmed TrelCor’s dual phase composition and a nanostructured HCA surface. Additional testing evaluated various advanced bone graft properties including bioactivity and in vivo stem cell stimulation. Results showed that TrelCor exhibited a robust bioactive response and was capable of stimulating bone forming cells.
The study’s findings underscore TrelCor’s efficacy in actively stimulating a bone formation response, which leads it to significantly outperforming traditional, first generation bone graft materials. TrelCor has undergone over 75,000 successful implantations.
Copy to clipboard 
